Comparison of Jakavi ® (ruxolitinib) vs. best available therapy presented at EHA suggests reduced risk of death in patients with inadequately controlled polycythemia vera (PV)[1] Additional data at ...

East Hanover-based Novartis announced Friday plans to initiate a Phase III clinical trial in collaboration with Incyte to evaluate the use of Jakavi (ruxolitinib) for treatment of a type of severe ...

Preplanned analysis at 18 months demonstrate 80% of PV patients treated with Jakavi ® (ruxolitinib) experienced a durable response for at least one year[1] In the study, 83% of patients in the Jakavi ...

Add Yahoo as a preferred source to see more of our stories on Google. A Novartis logo is pictured on its headquarters building in Mumbai February 6, 2014. REUTERS/Danish Siddiqui ZURICH (Reuters) - ...

New data shows Novartis' Jakavi to be superior than best available therapy in patients with the rare haematological cancer polycythemia vera (PV), which affects around 100,000 people globally a year.

Early clinical evidence suggests that the JAK inhibitor could reduce the number of patients requiring intensive care and mechanical ventilation As of this morning – Wednesday April 2 – the current ...

(RTTNews) - Novartis (NVS) said Friday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of ...

Jakavi is approved by the European Commission for the treatment of adult patients with polycythemia vera (PV) who are resistant to or intolerant of hydroxyurea and for the treatment of disease-related ...

Data from Phase III REACH2 study, published in The New England Journal of Medicine, demonstrate Jakavi can improve outcomes for patients with acute graft-versus-host disease (GvHD) who do not respond ...

ZURICH (Reuters) - Novartis drug Jakavi achieved its main goal in a late-stage trial for patients suffering from a rare blood cancer, putting it on track to become a potential blockbuster treatment ...